Affiliation:
1. Moscow State Autonomous Healthcare Institution «Moscow Scientific and Practical Centre of Medical Rehabilitation, Restorative and Sports Medicine of Moscow Health Care Department»; Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of Russia
2. Moscow State Autonomous Healthcare Institution «Moscow Scientific and Practical Centre of Medical Rehabilitation, Restorative and Sports Medicine of Moscow Health Care Department»
Abstract
The article discusses the principles of neuroprotective therapy as a pathogenetically justified direction in chronic cerebrovascular diseases (CVD). The results of numerous clinical trials demonstrated efficacy, safety, a wide range of pharmacological effects and good tolerability of the powerful antioxidant Idebenone (Neyromet), as well as domestic cytoprotector, Choline alphosceratus of (Cerepro®), affecting the basic pathophysiological processes of the ischemic cascade at CVD. The role of rational multimodal pharmacotherapy of CVD, which provides the necessary energy for the processes of neuroprotection and neuroplasticity of brain cells, is emphasized.
Reference51 articles.
1. Fedin A.I. Diagnosis and treatment of chronic cerebral ischemia. Consilium Medicum. 2016;18(2):8-12. (In Russ).
2. Johnston S.C., Nquyen-Huynh M.N., Schwarz M.E. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2008;60:301-303.
3. Vereshchagin N.V. et al. Brain pathology in atherosclerosis and arterial hypertension. M., 1997. (In Russ).
4. Nikiforov A.S., Konovalov A.N., Gusev E.I. Clinical neurology. M .: Medicine, 2002. (In Russ).
5. Gusev E.I., Skvortsova V.I., Cerebral ischemia. M.: Medicine, 2001. (In Russ).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献